1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990662
    Sapelizumab
    Inhibitor 98.31%
    Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    Sapelizumab
  • HY-168328
    FKK6
    Inhibitor 99.14%
    FKK6 is a selective agonist for pregnane X receptor (PXR) with an EC50 of 1.2 µM. FKK6 exhibits good affinity with plasma proteins, and good metabolic metabolism in human microsomes. FKK6 inhibits PXR-related NF-κB signaling pathway, inhibits the expression of inflammatory factors, and exhibits anti-inflammatory activity against DSS (HY-116282)-induced colitis in mouse model.
    FKK6
  • HY-P10420
    RS17
    99.82%
    RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.
    RS17
  • HY-150051
    IL-2-IN-1
    Inhibitor 99.95%
    IL-2-IN-1 is a potent IL-2 inhibitor with an IC50 value of 1978 nM. IL-2-IN-1 shows antiproliferative activities.
    IL-2-IN-1
  • HY-N7064
    Iminostilbene
    Inhibitor 99.34%
    Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
    Iminostilbene
  • HY-113618A
    RO2959 hydrochloride
    Inhibitor
    RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.
    RO2959 hydrochloride
  • HY-162248
    JAK1/2-IN-1
    Inhibitor 98.36%
    JAK1/2-IN-1 is a potent JAK1 and JAK2 inhibitor with IC50 values of 0.4 nM and 8.1 nM, respectively. JAK1/2-IN-1 also inhibits IL-4 and IL-13 with IC50s of 136.5 nM and 19.1 nM, respectively (WO2023244775A1; Example 33a).
    JAK1/2-IN-1
  • HY-P99659
    Imsidolimab
    Inhibitor 98.63%
    Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases.
    Imsidolimab
  • HY-131397
    Docosahexaenoyl serotonin
    Inhibitor ≥99.0%
    Docosahexaenoyl serotonin (DHA-5-HT) is an endogenous n-3 fatty acid-serotonin conjugate. Docosahexaenoyl serotonin is an inhibitor of IL-17. Docosahexaenoyl serotonin has anti-inflammatory activity.
    Docosahexaenoyl serotonin
  • HY-P99680
    Keliximab
    Inhibitor 98.23%
    Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.
    Keliximab
  • HY-139686
    IL-17A inhibitor 2
    Inhibitor 99.86%
    IL-17A inhibitor 2 is an IL-17A inhibitor for researching psoriasis, rheumatoid arthritis, and multiple sclerosis.
    IL-17A inhibitor 2
  • HY-N0247
    Saikosaponin B1
    Inhibitor 99.42%
    Saikosaponin B1 is a bioactive constituent of Radix Bupleuri. Saikosaponin B1 is an agonist of the 5-HT2C receptor with an EC50 of 147.41 μM. Saikosaponin B1 inhibits the Hedgehog (Hh) signaling pathway by targeting the transmembrane protein SMO. Sailosaponin B1 can reduce liver fibrosis. Saikosaponin B1 has anti-cancer activities thus can be studies in research for cancers such as Medulloblastoma (MB).
    Saikosaponin B1
  • HY-W004294
    1-Tetradecanol
    Inhibitor 99.34%
    1-Tetradecanol is a straight-chain saturated fatty alcohol and antibacterial agent. 1-Tetradecanol can be isolated from Myristica fragrans. 1-Tetradecanol possesses antibacterial and anti-inflammatory (periodontitis) activity.
    1-Tetradecanol
  • HY-P99754
    Netakimab
    Inhibitor
    Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab
  • HY-122941
    Viscidulin II
    Inhibitor
    Viscidulin II (FL6) is a flavone. Viscidulin II can be isolated from the root of Scutellaria baicalensis. Viscidulin II significantly suppresses P. acnes-induced IL-8 and IL-1β production in THP-1 cells.
    Viscidulin II
  • HY-W047478
    3-Methylcarbazole
    Inhibitor
    3-Methylcarbazole is an carbazole alkaloid compound with anticancer effects. 3-Methylcarbazole shows growth inhibitory activity (IC50 of 25 μg/mL) on human fibrosarcoma HT-1080 cells.
    3-Methylcarbazole
  • HY-153780
    Navepdekinra
    Inhibitor
    Navepdekinra (Example 210) is a potent interleukin-17A (IL-17A) inhibitor with anti-inflammatory activity.
    Navepdekinra
  • HY-P3211
    Nangibotide
    Inhibitor 98.27%
    Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
    Nangibotide
  • HY-18263A
    Elubrixin
    Antagonist
    Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
    Elubrixin
  • HY-P99490
    Burfiralimab
    Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
    Burfiralimab
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.